Skandinaviska Enskilda Banken AB publ Sells 1,057 Shares of Axon Enterprise, Inc $AXON

Skandinaviska Enskilda Banken AB publ lessened its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 6.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,874 shares of the biotechnology company’s stock after selling 1,057 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Axon Enterprise were worth $12,312,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in AXON. Banque Transatlantique SA purchased a new position in shares of Axon Enterprise in the 1st quarter worth $31,000. Flaharty Asset Management LLC bought a new position in Axon Enterprise in the first quarter valued at about $33,000. Hemington Wealth Management lifted its holdings in Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 17 shares during the period. Whipplewood Advisors LLC boosted its position in Axon Enterprise by 192.9% in the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 27 shares during the last quarter. Finally, NewSquare Capital LLC grew its stake in shares of Axon Enterprise by 96.2% during the 2nd quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 25 shares during the period. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Trading Up 1.3%

Shares of Axon Enterprise stock opened at $540.14 on Friday. Axon Enterprise, Inc has a fifty-two week low of $469.24 and a fifty-two week high of $885.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The company has a market capitalization of $42.62 billion, a P/E ratio of 133.37, a P/E/G ratio of 29.49 and a beta of 1.45. The company has a fifty day moving average of $658.44 and a 200 day moving average of $726.85.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). The business had revenue of $710.64 million during the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise’s revenue was up 30.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.45 earnings per share. On average, sell-side analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AXON. Cowen reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Wall Street Zen cut shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Raymond James Financial reissued an “outperform” rating and set a $855.00 price objective (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Finally, Craig Hallum raised Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price on the stock in a report on Tuesday, August 5th. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $814.00.

Insiders Place Their Bets

In other Axon Enterprise news, CAO Jennifer H. Mak sold 77 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $760.00, for a total value of $58,520.00. Following the completion of the transaction, the chief accounting officer directly owned 15,003 shares in the company, valued at $11,402,280. This represents a 0.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jeri Williams sold 100 shares of the stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total transaction of $75,254.00. Following the sale, the director directly owned 1,416 shares of the company’s stock, valued at approximately $1,065,596.64. This trade represents a 6.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 38,622 shares of company stock worth $26,439,364 over the last quarter. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.